


is hydrogen, C₁₋₄ alkyl, C₁₋₄ alkoxy or C₁₋₄ alkylthio, chloro, bromo, fluoro, trifluoromethyl, nitro, hydroxy, or amino, the latter optionally substituted by one or two C₁₋₄ alkyl groups, an acyl group or a C₁₋₄alkylsulfonyl group; A represents -CO or -CH₂- group; and n is 0, 1 or 2.


- 5 Exemplary indalpine structural analogs are indolyl-3 (piperidyl-4 methyl) ketone; (methoxy-5-indolyl-3) (piperidyl-4 methyl) ketone; (chloro-5-indolyl-3) (piperidyl-4 methyl) ketone; (indolyl-3)-1(piperidyl-4)-3 propanone, indolyl-3 piperidyl-4 ketone; (methyl-1 indolyl-3) (piperidyl-4 methyl) ketone, (benzyl-1 indolyl-3) (piperidyl-4 methyl) ketone; [(methoxy-5 indolyl-3)-2 ethyl]-piperidine,
10 [(methyl-1 indolyl-3)-2 ethyl]-4-piperidine; [(indolyl-3)-2 ethyl]-4 piperidine; (indolyl-3 methyl)-4 piperidine, [(chloro-5 indolyl-3)-2 ethyl]-4 piperidine; [(indolyl-b 3)-3 propyl]-4 piperidine; [(benzyl-1 indolyl-3)-2 ethyl]-4 piperidine; and pharmaceutically acceptable salts of any thereof.

15 Indeloxazine

Indeloxezine has the following structure:



Structural analogs of indeloxazine are those having the formula:




20

and pharmaceutically acceptable salts thereof, wherein R₁ and R₃ each represents hydrogen, C₁₋₄ alkyl, or phenyl; R₂ represents hydrogen, C₁₋₄ alkyl, C₄₋₇ cycloalkyl,


salts: cis-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine;
 cis-N-methyl-4-(4-bromophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine; cis-N-
 methyl-4-(4-chlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine; cis-N-methyl-4-
 (3-trifluoromethyl-phenyl)-1,2,3,4-tetrahydro-1-naphthalenamine; cis-N-methyl-4-
 5 (3-trifluoromethyl-4-chlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine; cis-
 N,N-dimethyl-4-(4-chlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine; cis-N,N-
 dimethyl-4-(3-trifluoromethyl-phenyl)-1,2,3,4-tetrahydro-1-naphthalenamine; and
 cis-N-methyl-4-(4-chlorophenyl)-7-chloro-1,2,3,4-tetrahydro-1-naphthalenamine.
 Of interest also is the (1R)-enantiomer of cis-N-methyl-4-(3,4-dichlorophenyl)-
 10 1,2,3,4-tetrahydro-1-naphthalenamine.

Zimeldine

Zimeldine has the following structure:



15 Structural analogs of zimeldine are those compounds having the formula:



and pharmaceutically acceptable salts thereof, wherein the pyridine nucleus is
 bound in ortho-, meta- or para-position to the adjacent carbon atom and where R₁
 is selected from the group consisting of H, chloro, fluoro, and bromo.

Atlas/ICI), sorbitan monostearate (Span-60, Atlas/ICI), sorbitan trioleate (Span-85, Atlas/ICI), sorbitan sesquioleate (Arlacel-C, ICI), sorbitan tristearate (Span-65, Atlas/ICI), sorbitan monoisostearate (Crill 6, Croda), and sorbitan sesquistearate (Nikkol SS-15, Nikko). Formulations of the SSRI/steroid combinations according to the invention may include one or more of the sorbitan fatty acid esters above.

Esters of lower alcohols (C_2 to C_4) and fatty acids (C_8 to C_{18}) are suitable surfactants for use in the invention. Examples of these surfactants include: ethyl oleate (Crodamol EO, Croda), isopropyl myristate (Crodamol IPM, Croda), isopropyl palmitate (Crodamol IPP, Croda), ethyl linoleate (Nikkol VF-E, Nikko), and isopropyl linoleate (Nikkol VF-IP, Nikko). Formulations of the SSRI/steroid combinations according to the invention may include one or more of the lower alcohol fatty acid esters above.

In addition, ionic surfactants may be used as excipients for the formulation of the SSRI/steroid combinations described herein. Examples of useful ionic surfactants include: sodium caproate, sodium caprylate, sodium caprate, sodium laurate, sodium myristate, sodium myristolate, sodium palmitate, sodium palmitoleate, sodium oleate, sodium ricinoleate, sodium linoleate, sodium linolenate, sodium stearate, sodium lauryl sulfate (dodecyl), sodium tetradecyl sulfate, sodium lauryl sarcosinate, sodium dioctyl sulfosuccinate, sodium cholate, sodium taurocholate, sodium glycocholate, sodium deoxycholate, sodium taurodeoxycholate, sodium glycodeoxycholate, sodium ursodeoxycholate, sodium chenodeoxycholate, sodium taurochenodeoxycholate, sodium glyco cheno deoxycholate, sodium cholylsarcosinate, sodium N-methyl taurocholate, egg yolk phosphatides, hydrogenated soy lecithin, dimyristoyl lecithin, lecithin, hydroxylated lecithin, lysophosphatidylcholine, cardiolipin, sphingomyelin, phosphatidylcholine, phosphatidyl ethanolamine, phosphatidic acid, phosphatidyl glycerol, phosphatidyl serine, diethanolamine, phospholipids, polyoxyethylene-10 oleyl ether phosphate, esterification products of fatty alcohols or fatty alcohol ethoxylates, with phosphoric acid or anhydride, ether carboxylates (by oxidation

Table 7—Paroxetine

μM	TNF α (PI)	TNF α (LPS)	IL-2	μM	IL-1 β	μM	IFN γ
27.00	94	80	88	53.00	64	33.35	97.58
13.50	87	13	71	26.50	39	16.68	73.92
6.75	66	0	21	13.25	24	8.34	52.8
3.38	44	0	6	6.63	0	4.17	27.93
1.69	30	0	0	3.31	0	2.08	16.48
0.84	16	0	0	1.66	0	1.04	4.26
0.42	13	0	0	0.83	0	0.52	2.42
0.21	11	0	0	0.41	0	0.26	-0.93
0.11	5	0	0	0.21	0	0.13	3.96
0.05	0	0	0	0.10	0	0.07	3.29
0.03	0	0	0	0.05	0	0.03	0.53

Table 8—Sertraline

μM	TNF α (PI)	TNF α (LPS)	IL-2	IL-1 β	μM	IFN γ
64.00	95	97	71	95	37.43	20
32.00	96	84	63	55	18.72	9
16.00	87	20	53	11	9.36	8
8.00	66	7	36	6	4.68	6
4.00	38	0	9	0	2.34	3
2.00	18	0	0	0	1.17	4
1.00	11	0	0	0	0.58	7
0.50	0	0	0	0	0.29	5
0.25	0	0	0	0	0.15	2
0.13	0	0	0	0	0.07	1
0.06	0	0	0	0	0.04	3
0.03	0	0	0	0	0.02	1

5

Table 9—Venlafaxine

μM	TNF α (PI)	TNF α (LPS)	IL-1 β	IL-2	IFN γ
39.83	-1.64	32.50	18.79	-19.45	-4.73
19.92	-0.61	24.15	0.66	-20.24	-9.95
9.96	-7.73	1.20	-6.19	-17.89	-6.69
4.98	-13.51	-18.41	-14.75	-20.77	-3.38
2.49	-12.83	0.10	-18.84	-14.09	-4.00
1.24	-12.55	8.77	-21.13	-18.48	2.25
0.62	-7.21	14.65	-14.89	-16.48	-1.52
0.31	-2.52	3.33	-15.56	-17.67	0.75
0.16	-6.08	-2.41	-21.72	-16.19	0.61
0.08	-7.55	3.33	-21.22	-12.90	3.22
0.04	-7.81	9.79	0.23	-10.03	0.01
0.02	-5.18	11.85	-9.54	-8.07	-1.27

Table 10—Norfluoxetine

μM	TNF α PI	TNF α LPS	IL-2	IL-1 β
45.00	96	70	77	68
22.50	86	0	66	0
11.25	57	0	32	0
5.63	22	0	14	0
2.81	0	0	7	0
1.41	0	0	0	0
0.70	0	0	0	0
0.35	0	0	0	0
0.18	0	0	0	0
0.09	0	0	0	0
0.04	0	0	0	0
0.02	0	0	0	0

Table 11—R(+) Fluoxetine

μM	TNF α (PI)	TNF α (LPS)	IL-2	IL-1 β
58	97	82	72	68
29	89	0	72	0
14.5	66	0	55	0
7.25	22	0	11	0
3.625	3	0	15	0
1.813	0	0	12	0
0.906	0	0	0	0
0.453	0	0	0	0
0.227	0	0	0	0
0.113	0	0	0	0
0.057	0	0	0	0
0.028	0	0	0	0

5

Table 12—S(+) Fluoxetine

μM	TNF α (PI)	TNF α (LPS)	IL-2	IL-1 β
58	98	72	62	76
29	94	45	66	70
14.5	70	0	55	31
7.25	48	0	17	0
3.625	20	0	0	0
1.813	18	0	0	0
0.906	12	0	0	0
0.453	6	0	0	0
0.227	7	0	0	0
0.113	0	0	0	0
0.057	0	0	0	0
0.028	0	0	0	0